Highly sensitive proximity mediated immunoassay reveals HER2 status conversion in the circulating tumor cells of metastatic breast cancer patients

BACKGROUND: The clinical benefits associated with targeted oncology agents are generally limited to subsets of patients. Even with favorable biomarker profiles, many patients do not respond or acquire resistance. Existing technologies are ineffective for treatment monitoring as they provide only sta...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Phillip, Liu, Xinjun, Lee, Tani, Liu, Limin, Barham, Robert, Kirkland, Richard, Leesman, Glen, Kuller, Anne, Ybarrondo, Belen, Ng, Shi-Chung, Singh, Sharat
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3271991/
https://www.ncbi.nlm.nih.gov/pubmed/22172159
http://dx.doi.org/10.1186/1477-5956-9-75

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3271991/
https://www.ncbi.nlm.nih.gov/pubmed/22172159
http://dx.doi.org/10.1186/1477-5956-9-75

Ejemplares similares